Document ID: chunk:federal_register_of_legislation:F2021L00014:reg:9:p1
Version: federal_register_of_legislation:F2021L00014
Segment Type: reg
Provision Reference: reg 9 (pt 1/3)
Character Range: 4016–7067

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting angle-closure glaucoma or death from angle-closure glaucoma with the circumstances of a person's relevant service:
(1)          taking a drug from the specified list of drugs within the 21 days before the clinical onset of angle-closure glaucoma;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(2)          taking a drug which causes:
(a)           mydriasis or miosis in the affected eye; or
(b)          an allergic or inflammatory reaction involving structures of the anterior segment of the affected eye;
within the 21 days before the clinical onset of angle-closure glaucoma;
(3)          having uveitis, scleritis or episcleritis at the time of the clinical onset of angle-closure glaucoma, where the disease involves the structures of the anterior chamber of the affected eye;
Note: uveitis, scleritis and episcleritis are defined in the Schedule 1 - Dictionary.
(4)          having:
(a)          a benign or malignant neoplasm; or
(b)          a non-neoplastic lesion;
which involves the anterior segment of the affected eye at the time of the clinical onset of angle-closure glaucoma;
            Note 1: Examples of a benign or malignant neoplasm include melanoma, retinoblastoma, leukaemia and lymphoma.
            Note 2: Examples of a non-neoplastic lesion include amyloidosis, cyst, ocular haemorrhage, retinal detachment and vascular malformation or thrombosis.
(5)          having a disorder of the lens of the affected eye at the time of the clinical onset of angle-closure glaucoma;
            Note: Examples of a disorder of the lens include cataract and lens displacement, subluxation or dislocation.
(6)          having growth of new blood vessels (neovascularisation) of the iridocorneal angle due to a condition or procedure involving the affected eye from the specified list of conditions or procedures, before the clinical onset of angle-closure glaucoma;
Note: specified list of conditions or procedures is defined in the Schedule 1 - Dictionary.
(7)          having trauma to the affected eye before the clinical onset of
angle-closure glaucoma;
Note: trauma is defined in the Schedule 1 - Dictionary.
(8)          having sympathetic ophthalmia at the time of the clinical onset of angle-closure glaucoma;
Note: sympathetic ophthalmia is defined in the Schedule 1 - Dictionary.
(9)          having surgery to the affected eye, or eyelid of the affected eye, before the clinical onset of angle-closure glaucoma;
(10)      having surgery requiring a general anaesthetic, or surgery in the prone position, within the 21 days before the clinical onset of angle-closure glaucoma;
(11)      undergoing a course of therapeutic radiation for cancer, where the affected eye was in the field of radiation, before the clinical onset of angle-closure glaucoma;
(12)      taking a drug from the specified list of drugs within the